CJC-1295 + Ipamorelin
Same price per vial — no bulk discount, just add more to one order.
20% off included — code WELCOME20 is reflected in this price and applied automatically at checkout.
For laboratory research use only · Not for human consumption · Read handling terms →
Lab-grade material. Proof in every order.
Third-party HPLC, mass-spec, and endotoxin testing on every batch — with the Certificate of Analysis included, not on request.
Overview+
This is a commonly paired secretagogue combination used in growth-hormone-axis research. CJC-1295 is studied as a growth-hormone-releasing hormone analog, while ipamorelin acts as a selective ghrelin-receptor agonist. Because the two engage different receptors that both feed into growth-hormone output, they are examined together for complementary effects on pulsatile signaling in laboratory models.
History+
CJC-1295 was developed in the 2000s as a long-acting GHRH analog, and ipamorelin (code NNC 26-0161) was developed by Novo Nordisk in the late 1990s as a selective pentapeptide secretagogue. Combining a GHRH analog with a growth-hormone-secretagogue-receptor agonist is a long-standing experimental design for probing how two distinct inputs converge on secretory signaling.
Structure & specifications+
Research findings+
The combination has been studied in preclinical endocrine models for parallel activity on the GHRH receptor and the growth-hormone-secretagogue receptor, with particular interest in secretory-pulse dynamics. Pairing the two lets researchers separate the contribution of each receptor while observing how they interact, since one extends the signaling window and the other drives sharper secretory pulses. As a combined preparation it serves as a convenient reference point for studies of synergistic endocrine signaling in the laboratory.
- →Endocrine: GHRH-receptor and GHS-receptor signaling
- →Metabolic: IGF-1 axis dynamics
- →Systemic: Pulsatile secretion, pathway modulation
Shipping, storage & handling+
Same-day dispatch before 2:00 PM CST, Monday through Saturday. Store lyophilized vials at −20°C, protected from light; reconstituted solutions at 2–8°C. Discreet, temperature-safe packaging. Guaranteed delivery with free reshipment.
References+
- Teichman SL. et al. (2006). Pharmacology of a long-acting GHRH analog.
- Raun K. et al. (1998). Characterization of a selective GH secretagogue.
- Ionescu M. & Frohman LA. (2006). Secretagogue effects on GH pulsatility.
What’s actually in your vial?
Most researchers don’t ask. The ones who do, switch.
Text us, our dedicated team is here to help.
Reach out and get a response within minutes.
